kloh-PID-oh-grel
REMS
Contraindicated in:
CYP2C19 poor metabolizers
.Use Cautiously in:
CV: chest pain, edema, hypertension
Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS, DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, pruritus, purpura, rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN)
EENT: epistaxis
GI: abdominal pain, diarrhea, dyspepsia, gastritis, GI BLEEDING
Hemat: BLEEDING, NEUTROPENIA, THROMBOTIC THROMBOCYTOPENIC PURPURA
MS: arthralgia, back pain
Neuro: depression, dizziness, fatigue, headache
Resp: cough, dyspnea, eosinophilic pneumonia
Misc: fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)
Drug-drug:
Drug-Natural Products:
Acute Coronary Syndrome
Recent MI, Stroke, or Peripheral Arterial Disease
Therapeutic Classification: antiplatelet agents
Pharmacologic Classification: platelet aggregation inhibitors
Absorption: Well absorbed following oral administration; prodrug that is rapidly metabolized to an active antiplatelet compound. Parent drug has no antiplatelet activity.
Distribution: Unknown.
Protein Binding: Clopidogrel: 98%; active metabolite: 94%.
2% of White people, 4% of Black people, and 14% of Asian people have CYP2C19 genotype, which results in reduced metabolism of clopidogrel (poor metabolizers) into its active metabolite (may result in ↓ antiplatelet effects)
.Half-Life: 6 hr (active metabolite 30 min).
(effects on platelet function)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | within 24 hr | 3–7 days | 5 days‡ |
‡Following discontinuation.
NDC Code
